Extracellular matrix turnover biomarkers reflect pharmacodynamic effects and treatment response of adalimumab in patients with axial spondyloarthritis —results from two randomized controlled trials

To investigate if extracellular matrix (ECM) blood-based biomarkers reflect the pharmacodynamic effect and response to TNF- α inhibitor therapy (adalimumab, ADA), in patients with axial spondyloarthritis (axSpA).

Source: Arthritis Research and Therapy - August 25, 2023 Category: Rheumatology Authors: Helena Port, Signe Holm Nielsen, Peder Frederiksen, Sofie Falkenl øve Madsen, Anne-Christine Bay-Jensen, Inge Juul Sørensen, Bente Jensen, Anne Gitte Loft, Ole Rintek Madsen, Mikkel Østergaard and Susanne Juhl Pedersen Tags: Research Source Type: research